ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.2700
+0.0400 (+3.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.2300
Open1.2500
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range1.2150 - 1.3000
52 Week Range1.2140 - 24.6000
Volume204,930
Avg. Volume248,619
Market Cap10.186M
Beta (3Y Monthly)4.12
PE Ratio (TTM)N/A
EPS (TTM)-6.9980
Earnings DateSep 9, 2019 - Sep 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.65
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

    Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced new immune data from its ongoing ADXS-NEO Phase 1 clinical trial that further support the clinical potential for the company’s platform in neoantigen-directed immunotherapies. ADXS-NEO is a personalized immunotherapy that is designed to help a patient’s immune system recognize and respond to mutation-derived tumor antigens, or neoantigens, that are unique to his or her tumor. ADXS-NEO is designed to express tLLO fused to up to 40 patient-specific neoantigens arranged sequentially as beads-on-a-string.

  • Business Wire25 days ago

    Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study

    Advaxis, Inc. (ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risk locally advanced cervical cancer. Advaxis intends to continue to support the clinical development of AXAL, its single-antigen construct, in other HPV-related cancers while redirecting resources towards advancing its neoantigen-directed programs.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT

    Q2 2019 Advaxis Inc Earnings Call

  • ACCESSWIRElast month

    Advaxis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Advaxis, Inc. (NASDAQ: ADXS ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on June 11, 2019 at 11:00 AM Eastern ...

  • Business Wirelast month

    Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

    Conference call to be held June 11 at 11:00 a.m. ET

  • Business Wire2 months ago

    Advaxis to Host Business Update Conference Call on June 11, 2019

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET. During the call, Advaxis’ senior management will review the company’s clinical development programs and recent financial results, and provide a general business update. The company intends to issue a news release summarizing financial results for the fiscal second quarter ended April 30, 2019 after market close on Monday, June 10, 2019.

  • What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?
    Simply Wall St.2 months ago

    What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?

    The big shareholder groups in Advaxis, Inc. (NASDAQ:ADXS) have power over the company. Large companies usually have...

  • Benzinga2 months ago

    Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug

    Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...

  • Business Wire2 months ago

    FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions. As announced on January 23, 2019, the FDA placed a partial clinical hold on this study relating to the Agency’s requests for additional information pertaining to certain AXAL chemistry, manufacturing and controls (CMC) matters. The Agency did not cite any safety issues related to the trial and all enrolled patients continued to receive treatment, per the trial protocol.

  • Business Wire2 months ago

    Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being held today at the New York Academy of Sciences in New York City. Both posters were first presented at the recent American Association for Cancer Research (AACR) Annual Meeting, and each has updated findings being presented today. The first presentation regarding a poster entitled “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)” is conference poster #31, and will be presented by Robert Petit, Ph.D., Advaxis Chief Scientific Officer, and Mark N. Stein, M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center, from 4:45 to 5:30 p.m. Eastern time.

  • Business Wire2 months ago

    Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month. Dr. Petit will assist the Company in transitioning his duties over the next several weeks, and will continue to support the Company as an advisor and consultant in his capacity as the new Chair of the Advaxis Scientific Advisory Board, effective June 3, 2019.

  • Business Wire2 months ago

    Advaxis to Participate in Five Upcoming Industry Conferences

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in f

  • Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
    Zacks3 months ago

    Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

    Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

  • QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
    Zacks3 months ago

    QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

    QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

  • Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
    Zacks3 months ago

    Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
    Zacks3 months ago

    Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?

    Is (ADXS) Outperforming Other Medical Stocks This Year?

  • Why Range Resources, Advaxis, and StoneCo Slumped Today
    Motley Fool4 months ago

    Why Range Resources, Advaxis, and StoneCo Slumped Today

    Equity offerings played a big role for two of these companies.

  • Benzinga4 months ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • Business Wire4 months ago

    Advaxis Announces Pricing of Its Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $4.00 per share. The gross proceeds to Advaxis, Inc. from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • Business Wire4 months ago

    Advaxis, Inc. Announces Proposed Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it intends to offer and sell in an underwritten public offering shares of its common stock. Electronic copies of the preliminary prospectus supplement and prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or via email at prospectus@allianceg.com.

  • Advaxis Up on Positive Early-Stage Immunotherapy Study Data
    Zacks4 months ago

    Advaxis Up on Positive Early-Stage Immunotherapy Study Data

    Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.

  • Why Wynn Resorts, Advaxis, and Roku Jumped Today
    Motley Fool4 months ago

    Why Wynn Resorts, Advaxis, and Roku Jumped Today

    These stocks jumped on a strong start to the second quarter.

  • Why Advaxis Stock Skyrocketed 13.8% Today
    Motley Fool4 months ago

    Why Advaxis Stock Skyrocketed 13.8% Today

    The small-cap biotech reported encouraging news about its prostate cancer therapy.

  • Benzinga4 months ago

    Advaxis Shares Surge After Positive Clinical Trial Updates

    Advaxis, Inc. (NASDAQ: ADXS ) has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days. Investors have viewed the developments ...